News | ASTRO | November 01, 2019

ASTRO supports nomination of Stephen Hahn, M.D., FASTRO, to lead U.S. FDA

Hahn has served on the ASTRO Board of Directors and has broad knowledge as a clinician, researcher, educator and administrative leader

Stephen Hahn, M.D., FASTRO

Stephen Hahn, M.D., FASTRO

November 1, 2019 — The American Society for Radiation Oncology (ASTRO) today expressed strong support for the nomination of radiation oncologist Stephen Hahn, M.D., FASTRO, as Commissioner of the Food and Drug Administration (FDA). Hahn served on the ASTRO Board of Directors from 2014 to 2018. ASTRO urges the Senate to swiftly confirm the nomination announced today by President Donald Trump.

Hahn has broad knowledge as a clinician, researcher, educator and administrative leader, and he previously obtained the rank of commander in the U.S. Public Health Service. He is well-versed on the drug, biologic and device development pipeline, demonstrated by his role in developing multiple medical products. His clinical expertise and training in internal medicine, medical oncology and radiation oncology, as well as his international recognition in treating lung cancer give him the ability to tackle some of the toughest issues faced by the FDA.

Several members of ASTRO's leadership who have worked with Hahn shared their support of his nomination:

"I have known Dr. Hahn for many years and have served with him in numerous capacities.  He possesses the qualities needed to successfully lead the FDA … intelligence, medical and scientific expertise, an engaging style and a clear sense of how to get to the right answer, particularly in complicated situations.”

Theodore L. DeWeese, M.D., FASTRO; Chair, ASTRO Board of Directors 2019-2020; Vice Dean for Clinical Affairs, Sidney Kimmel Professor and Director of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine

"During his tenure on the ASTRO Board, Dr. Hahn always brought insightful questions to our deliberations. He takes the time to listen to all sides before he reaches a decision, which will be important in this new role. I also don't know that I have ever seen anyone who can cover as much ground as he can cover. His depth of knowledge will allow him to accomplish the many tasks ahead as FDA Commissioner.”

Laura I. Thevenot; Chief Executive Officer, ASTRO

"Dr. Hahn is a brilliant physician leader with the highest levels of integrity and problem-solving talent.  With a background in radiation oncology and medical oncology, he is uniquely positioned to advance the crucial work of the FDA.”

Ronald Ennis, M.D., FASTRO; Government Relations Council Chair, ASTRO Board of Directors 2019-2020; Associate Professor of Radiation Oncology, Icahn School of Medicine at Mount Sinai

 

ASTRO previously expressed its support of Dr. Hahn after news reports in September suggested he was being considered for the FDA leadership post. That statement, from then-ASTRO Chair Paul Harari, M.D., FASTRO, noted how Dr. Hahn's clinical experience could translate into success leading the FDA:

"A culture of safety is woven into the fabric of radiation oncology, making Dr. Hahn expertly suited to further FDA’s mission of protecting the public health. At the same time, Dr. Hahn’s experience using some of the most sophisticated medical devices in health care gives him insight and expertise to drive progress for the benefit of patients and consumers."

Paul Harari, M.D., FASTRO; Chair, ASTRO Board of Directors 2018-2019; Jack Fowler Professor and Chairman of Human Oncology, University of Wisconsin School of Medicine and Public Health

 

For more information: www.astro.org

 

Related Content

RaySearch Laboratories AB (publ) has experienced strong growth in recent years, creating the need for larger and more efficient premises
News | Radiation Therapy | December 09, 2019
December 9, 2019 — Karin Gedda, architect and i
Legislation ends surprise medical bills; funds Community Health Centers for five years; increases the purchasing age of tobacco to 21; lowers prescription drug and other medical costs by requiring more transparency and competition
News | Population Health | December 09, 2019
December 9, 2019 — Senate Health Committee Chairman...
•	Sports Imaging is a unique specialty that allows radiologists to collaborate across the care continuum from detection to treatment

Image courtesy of Carestream Health

Feature | Radiology Business | November 18, 2019 | By Neelesh S. Prakash, M.D.
International Radiology Day (IDoR
Image by Pexels from Pixabay RSNA 2019

Image by Pexels from Pixabay 

News | RSNA | November 15, 2019
November 15, 2019 – The 105th Scientific Assembly and Annual Meeting of the...
Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
The ALS produces various wavelengths of bright light that can be used to explore the microscopic chemistry, structure, and other properties of samples

Two researchers from Cairo University in Egypt brought 32 bone samples and two soil samples to study using X-ray and infrared light-based techniques at Berkeley Lab's Advanced Light Source (ALS). The ALS produces various wavelengths of bright light that can be used to explore the microscopic chemistry, structure, and other properties of samples. Image courtesy of Marilyn Sargent/Berkeley Lab

News | Radiology Imaging | November 13, 2019
November 13, 2019 — Experiments at the Department of Energy's Lawrence Berkeley National Laboratory (...